BCTX - BriaCell Therapeutics' Cancer Drug Shows Preliminary Survival Clinical Benefit In Pretreated Patients | Benzinga
BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell's Bria-IMT regimen: patients that have developed resistance to (and failed to respond to) Antibody-Drug Conjugates (ADCs).
Kaplan-Meier analysis showed median overall survival (OS) that was up to ...